-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Ovid Therapeutics, Raises Price Target to $4

Benzinga·04/09/2026 11:32:39
Listen to the news
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Ovid Therapeutics (NASDAQ:OVID) with a Buy and raises the price target from $2 to $4.